IDEXX Laboratories, Inc. $IDXX Shares Sold by Everhart Financial Group Inc.

Key Points

• Everhart Financial Group cut its IDEXX Laboratories stake by 61.9% in the third quarter, selling 3,025 shares and retaining 1,865 shares worth approximately $974,000. Institutional investors and hedge funds collectively own 87.84% of the stock.
• IDEXX reported quarterly earnings of $4.27 per share, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. The company maintained fiscal 2026 EPS guidance of $14.69–$14.94.
• The stock opened at $513.14, near its 12-month low of $500.61, despite a 1.3% daily gain. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $747, although one director recently sold shares and several firms lowered or maintained neutral ratings.

Everhart Financial Group Inc. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 61.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,865 shares of the company's stock after selling 3,025 shares during the quarter. Everhart Financial Group Inc.'s holdings in IDEXX Laboratories were worth $974,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Triad Wealth Partners LLC increased its position in IDEXX Laboratories by 3.1% during the 1st quarter. Triad Wealth Partners LLC now owns 600 shares of the company's stock worth $337,000 after purchasing an additional 18 shares in the last quarter. KCM Investment Advisors LLC boosted its position in IDEXX Laboratories by 5.3% in the fourth quarter. KCM Investment Advisors LLC now owns 377 shares of the company's stock valued at $255,000 after buying an additional 19 shares in the last quarter. Arlington Trust Co LLC boosted its position in IDEXX Laboratories by 46.3% in the second quarter. Arlington Trust Co LLC now owns 60 shares of the company's stock valued at $32,000 after buying an additional 19 shares in the last quarter. Evolve Private Wealth LLC grew its stake in shares of IDEXX Laboratories by 3.2% during the first quarter. Evolve Private Wealth LLC now owns 640 shares of the company's stock worth $360,000 after buying an additional 20 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC grew its stake in shares of IDEXX Laboratories by 21.4% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 119 shares of the company's stock worth $67,000 after buying an additional 21 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the transaction, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. This trade represents a 18.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.79% of the company's stock.

IDEXX Laboratories Trading Up 1.3%

NASDAQ IDXX opened at $513.14 on Friday. The business's 50-day moving average price is $539.78 and its two-hundred day moving average price is $553.31. IDEXX Laboratories, Inc. has a 12 month low of $500.61 and a 12 month high of $769.98. The firm has a market capitalization of $40.43 billion, a PE ratio of 36.09, a price-to-earnings-growth ratio of 2.70 and a beta of 1.55. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The company had revenue of $1.22 billion during the quarter, compared to analysts' expectations of $1.20 billion. During the same quarter in the prior year, the firm posted $3.50 earnings per share. The business's quarterly revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.81 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Weiss Ratings cut IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research note on Thursday, August 27th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Sunday, July 12th. Barclays lowered their target price on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Citigroup increased their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research report on Wednesday, August 5th. Finally, UBS Group lifted their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Six investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $747.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.